Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasms.

Fütterer A, Campanero MR, Leonardo E, Criado LM, Flores JM, Hernández JM, San Miguel JF, Martínez-A C.

J Clin Invest. 2005 Sep;115(9):2351-62. Epub 2005 Aug 25.

2.

Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. UK Cancer Cytogenetics Group (UKCCG).

Bench AJ, Nacheva EP, Hood TL, Holden JL, French L, Swanton S, Champion KM, Li J, Whittaker P, Stavrides G, Hunt AR, Huntly BJ, Campbell LJ, Bentley DR, Deloukas P, Green AR.

Oncogene. 2000 Aug 10;19(34):3902-13.

3.

Prognostic significance of del(20q) in patients with hematological malignancies.

Brezinová J, Zemanová Z, Ransdorfová S, Sindelárová L, Sisková M, Neuwirtová R, Cermák J, Michalová K.

Cancer Genet Cytogenet. 2005 Jul 15;160(2):188-92.

PMID:
15993278
4.

Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis.

Huh J, Tiu RV, Gondek LP, O'Keefe CL, Jasek M, Makishima H, Jankowska AM, Jiang Y, Verma A, Theil KS, McDevitt MA, Maciejewski JP.

Genes Chromosomes Cancer. 2010 Apr;49(4):390-9. doi: 10.1002/gcc.20748.

PMID:
20095039
5.
6.

Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia-chromosome-negative myeloproliferative disorders: characterization by molecular cytogenetics of commonly deleted and retained regions.

Douet-Guilbert N, Basinko A, Morel F, Le Bris MJ, Ugo V, Morice P, Berthou C, De Braekeleer M.

Ann Hematol. 2008 Jul;87(7):537-44. doi: 10.1007/s00277-008-0462-3. Epub 2008 Mar 19.

PMID:
18350294
7.

Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations.

Russell M, List A, Greenberg P, Woodward S, Glinsmann B, Parganas E, Ihle J, Taetle R.

Blood. 1994 Aug 15;84(4):1243-8.

8.

Deletions of chromosome 20q and the pathogenesis of myeloproliferative disorders.

Asimakopoulos FA, Green AR.

Br J Haematol. 1996 Nov;95(2):219-26. Review.

PMID:
8904873
9.

Deletion of chromosome 20q in myelodysplasia can occur in a multipotent precursor of both myeloid cells and B cells.

White NJ, Nacheva E, Asimakopoulos FA, Bloxham D, Paul B, Green AR.

Blood. 1994 May 15;83(10):2809-16.

10.

Mutation in TET2 in myeloid cancers.

Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A, Kosmider O, Le Couedic JP, Robert F, Alberdi A, Lécluse Y, Plo I, Dreyfus FJ, Marzac C, Casadevall N, Lacombe C, Romana SP, Dessen P, Soulier J, Viguié F, Fontenay M, Vainchenker W, Bernard OA.

N Engl J Med. 2009 May 28;360(22):2289-301. doi: 10.1056/NEJMoa0810069.

11.

Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institution.

Santana-Davila R, Holtan SG, Dewald GW, Ketterling RP, Knudson RA, Hanson CA, Steensma DP, Tefferi A.

Leuk Res. 2008 Mar;32(3):407-11. Epub 2007 Aug 20.

PMID:
17707907
12.

Dido disruption leads to centrosome amplification and mitotic checkpoint defects compromising chromosome stability.

Trachana V, van Wely KH, Guerrero AA, Fütterer A, Martínez-A C.

Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2691-6. Epub 2007 Feb 13.

13.

Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patients.

Patnaik MM, Lasho TL, Finke CM, Knudson RA, Ketterling RP, Chen D, Hoyer JD, Hanson CA, Tefferi A.

Am J Hematol. 2011 May;86(5):393-8. doi: 10.1002/ajh.21984.

14.
15.

SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice.

Ma Y, Cui W, Yang J, Qu J, Di C, Amin HM, Lai R, Ritz J, Krause DS, Chai L.

Blood. 2006 Oct 15;108(8):2726-35. Epub 2006 Jun 8.

16.

Molecular bases of myelodysplastic syndromes: lessons from animal models.

Komeno Y, Kitaura J, Kitamura T.

J Cell Physiol. 2009 Jun;219(3):529-34. doi: 10.1002/jcp.21739. Review.

PMID:
19259975
17.

The mammalian HSF4 gene generates both an activator and a repressor of heat shock genes by alternative splicing.

Tanabe M, Sasai N, Nagata K, Liu XD, Liu PC, Thiele DJ, Nakai A.

J Biol Chem. 1999 Sep 24;274(39):27845-56.

18.

Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes.

Mann KP, DeCastro CM, Liu J, Moore JO, Bigner SH, Traweek ST.

Am J Clin Pathol. 1997 Jun;107(6):653-60.

PMID:
9169661
19.

The Tel-PDGFRbeta fusion gene produces a chronic myeloproliferative syndrome in transgenic mice.

Ritchie KA, Aprikyan AA, Bowen-Pope DF, Norby-Slycord CJ, Conyers S, Bartelmez S, Sitnicka EH, Hickstein DD.

Leukemia. 1999 Nov;13(11):1790-803.

PMID:
10557054
20.

Analysis of the erythropoietin receptor gene in patients with myeloproliferative and myelodysplastic syndromes.

Mittelman M, Gardyn J, Carmel M, Malovani H, Barak Y, Nir U.

Leuk Res. 1996 Jun;20(6):459-66.

PMID:
8709617

Supplemental Content

Support Center